Throughout the last three months, 8 analysts have evaluated Hims & Hers Health HIMS, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 4 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 3 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Hims & Hers Health and provided 12-month price targets. The average target is $19.5, accompanied by a high estimate of $26.00 and a low estimate of $13.00. Observing a 16.42% increase, the current average has risen from the previous average price target of $16.75.
Interpreting Analyst Ratings: A Closer Look
A comprehensive examination of how financial experts perceive Hims & Hers Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Cherny | B of A Securities | Raises | Buy | $26.00 | $22.00 |
| Michael Cherny | B of A Securities | Raises | Buy | $22.00 | $17.25 |
| Maria Ripps | Canaccord Genuity | Raises | Buy | $24.00 | $20.00 |
| Daniel Grosslight | Citigroup | Raises | Neutral | $20.00 | $16.00 |
| George Hill | Deutsche Bank | Raises | Hold | $16.00 | $14.00 |
| Korinne Wolfmeyer | Piper Sandler | Raises | Neutral | $13.00 | $11.00 |
| Glen Santangelo | Jefferies | Lowers | Hold | $15.00 | $17.00 |
| Maria Ripps | Canaccord Genuity | Announces | Buy | $20.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hims & Hers Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Hims & Hers Health compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Hims & Hers Health's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Hims & Hers Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Hims & Hers Health analyst ratings.
Get to Know Hims & Hers Health Better
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Hims & Hers Health: Financial Performance Dissected
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Hims & Hers Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 45.81% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Hims & Hers Health's net margin is impressive, surpassing industry averages. With a net margin of 4.0%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Hims & Hers Health's ROE excels beyond industry benchmarks, reaching 3.23%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Hims & Hers Health's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.5%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
Understanding the Relevance of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
